GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » Price-to-Tangible-Book

C4 Therapeutics (C4 Therapeutics) Price-to-Tangible-Book : 1.67 (As of May. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is C4 Therapeutics Price-to-Tangible-Book?

As of today (2024-05-08), C4 Therapeutics's share price is $6.81. C4 Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $4.07. Hence, C4 Therapeutics's Price to Tangible Book Ratio of today is 1.67.

The historical rank and industry rank for C4 Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

CCCC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1   Med: 2.71   Max: 5.08
Current: 1.67

During the past 6 years, C4 Therapeutics's highest Price to Tangible Book Ratio was 5.08. The lowest was 1.00. And the median was 2.71.

CCCC's Price-to-Tangible-Book is ranked better than
70.29% of 1222 companies
in the Biotechnology industry
Industry Median: 2.73 vs CCCC: 1.67

A closely related ratio is called PB Ratio. As of today, C4 Therapeutics's share price is $6.81. C4 Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $4.07. Hence, C4 Therapeutics's P/B Ratio of today is 1.67.


C4 Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for C4 Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Price-to-Tangible-Book Chart

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial - 5.08 4.02 1.00 1.39

C4 Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 0.59 0.58 0.42 1.39

Competitive Comparison of C4 Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, C4 Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C4 Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, C4 Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where C4 Therapeutics's Price-to-Tangible-Book falls into.



C4 Therapeutics Price-to-Tangible-Book Calculation

C4 Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=6.81/4.07
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


C4 Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


C4 Therapeutics (C4 Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
Executives
Mark Mossler officer: Chief Accounting Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Kendra Adams officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Leonard Reyno officer: Chief Medical Officer 607 NORTH LAS PALMAS AVENUE, LOS ANGELES CA 90004
Utpal Koppikar director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Laura Bessen director 4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Andrew Hirsch director, officer: See Remarks C/O BIND THERAPEUTICS, INC., 325 VASSAR ST, CAMBRIDGE MA 02139
Kelly Schick officer: Chief People Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott N Boyle officer: Chief Business Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Malcolm Salter director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Adam Crystal officer: Chief Medical Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Elena Prokupets director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel officer: Chief Legal Officer C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher officer: Chief Scientific Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Lauren White officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472

C4 Therapeutics (C4 Therapeutics) Headlines

From GuruFocus

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023